
Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type …

UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has …

A study conducted by researchers at UT Southwestern’s Simmons Cancer Center has revealed that a combination of two specific drug …

A surprise new name was thrown into the ring to take on Pfizer’s healthcare unit but speculation suggests that valuation …

After working to bring through Kite Pharma from the pre-clinical development stage to its final $12 billion acquisition by Gilead, …

Ingrid Copperman recounts the many ways she has dealt with her diagnosis, as well as how the power of social …

NHS England is trialling centres that should be able to provide rapid answers as to whether a patient has cancer …

Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move …

AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …

Celgene has had a rough six months, its share price since the beginning of October has dropped from $146 to …

As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …

Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …

Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that …